By Topic
Black Cat Syndicate (ASX: BC8): Gold Production Surges as New High-Grade Discoveries Fuel Future Growth
Black Cat Syndicate (ASX: BC8) is a speculative mid-cap gold producer advancing Kal East, Paulsens, Coyote, and Mt Clement projects. Recent production growth, discoveries, and resource expansion support its long-term growth strategy.
Buru Energy (ASX: BRU): A Multi-Year Downtrend Meets Renewed Hope on New Project Funding
Buru Energy (ASX: BRU) is a pre-production explorer advancing its Rafael Gas Project toward a mid-2027 investment decision. Shares remain near 52-week lows, but funding progress, reserves certification, bullish divergence and trendline breakout potential offer catalysts amid significant dilution and execution risks.
Has Neuren Pharmaceuticals' (NEU) share price bottomed out?
If you bought Neuren Pharmaceuticals (ASX: NEU) near its peak, the recent volatility has been uncomfortable. Despite having its first approved drug for a rare paediatric disorder, growing royalty income and a promising pipeline, the share price has repeatedly rallied and retraced over the past two years. The key question now is whether NEU has already formed a durable bottom — or if another leg down could still test investor conviction.
CETTIRE's (ASX: CTT) share price is back to all time low levels, is it time to buy?
Recent tariff changes and trade frictions have disrupted that advantage and slowed growth. However, CETTIRE’s flexible, low-cost structure suggests its core model remains intact, leaving the company with meaningful long-term profit potential despite the current uncertainty around customer growth and demand.
Meeka Metals (ASX: MEK) Tests Major Support: Can the Downtrend Stabilise?
Meeka Metals faces selling pressure near key support after a volatile year, amid operational challenges and cautious sentiment. As it transitions to production at Murchison, investors are watching whether support holds or signals further downside despite long-term growth potential.
What is the reason for the plummet in Dimerix (ASX: DXB) share price, and how much lower can it go?
Dimerix shares plunged 35–40% amid heavy selling and uncertainty around clinical updates, worsened by weak biotech sentiment. Further downside depends on results and the funding outlook, though volatility in early-stage biotech stocks suggests a potential for sharp rebounds.
...